TNFα antagonist use has been linked with a reduced risk of MI and development of acute coronary syndrome, highlighting anti-TNFα therapy as a promising anti-atherosclerotic therapy in rheumatoid arthritis patients (Table 1) [144,145]. This evidence concerns the gene TNF and rheumatoid arthritis.